• Home

  • Documents

  • scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137...
5

scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 [email protected] : 0/0 5 Il Head Office

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 2: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 3: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 4: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 5: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify

Documents
COMPANY PROFILE EXCELLENT - Pharmaexcellent-pharma.com/wp-content/uploads/2016/11/Company-Profile.pdfleading companies through various agreements, partnerships and joint ventures,

COMPANY PROFILE EXCELLENT - Pharmaexcellent-pharma.com/wp-content/uploads/2016/11/Company-Profile.pdfleading companies through various agreements, partnerships and joint ventures,

Documents
Investor Presentation - Amazon S3 · Presentation FY 2017 Audited Results ... Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical

Investor Presentation - Amazon S3 · Presentation FY 2017 Audited Results ... Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical

Documents
TIM GASTROINTESTINAL TESTING - TNO Japan …tno-pharma.com/TIM_2017.pdfTIM GASTROINTESTINAL TESTING Triskelion tests and analyses chemical, pharmaceutical and biotechnology products,

TIM GASTROINTESTINAL TESTING - TNO Japan …tno-pharma.com/TIM_2017.pdfTIM GASTROINTESTINAL TESTING Triskelion tests and analyses chemical, pharmaceutical and biotechnology products,

Documents
PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/PROGRAM_20-01-2020.pdf · CRIUM, Hyderabad, INDIA Topic: Emerging trends in the management of Vitiligo IbnSina

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/PROGRAM_20-01-2020.pdf · CRIUM, Hyderabad, INDIA Topic: Emerging trends in the management of Vitiligo IbnSina

Documents
Investor Webinar - investor.xenon-pharma.com

Investor Webinar - investor.xenon-pharma.com

Documents
INVESTOR PRESENTATION - love-pharma.com

INVESTOR PRESENTATION - love-pharma.com

Documents
Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4

Documents
Dr. Mohammed N. Sabir 2021 - suli-pharma.com

Dr. Mohammed N. Sabir 2021 - suli-pharma.com

Documents
Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Documents
Peptic ulcer disease - suli-pharma.com

Peptic ulcer disease - suli-pharma.com

Documents
CLINICAL STUDY REPORT - leo-pharma.comleo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial...clinical study report investigation on the acceptability of calcipotriol solution

CLINICAL STUDY REPORT - leo-pharma.comleo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial...clinical study report investigation on the acceptability of calcipotriol solution

Documents
Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Documents
Ibnsina Pharma Releases 9M2019 Results · Market Overview According to data published by IMS Health, Egypt’s retail pharmaceutical market recorded total sales of EGP 55.2 billion

Ibnsina Pharma Releases 9M2019 Results · Market Overview According to data published by IMS Health, Egypt’s retail pharmaceutical market recorded total sales of EGP 55.2 billion

Documents
Sales Force Effectiveness - Channel Optimizationchannel-optimization-pharma.com/wp-content/uploads/sites/214/2017/...Sales Force Effectiveness ... ZS Associates Access Monitor™ 2015

Sales Force Effectiveness - Channel Optimizationchannel-optimization-pharma.com/wp-content/uploads/sites/214/2017/...Sales Force Effectiveness ... ZS Associates Access Monitor™ 2015

Documents
ATACs fighting Cancer - heidelberg-pharma.com · ATACs fighting Cancer March 21, 2019 FY 2018 Financial Results & Business Update

ATACs fighting Cancer - heidelberg-pharma.com · ATACs fighting Cancer March 21, 2019 FY 2018 Financial Results & Business Update

Documents
WILEX AG: Innovative Cancer Therapiesheidelberg-pharma.com/pdf/Download/200711 WILEX Therapies.pdf · Cancer disease life cycle Patient selection for therapy WILEX addresses markets

WILEX AG: Innovative Cancer Therapiesheidelberg-pharma.com/pdf/Download/200711 WILEX Therapies.pdf · Cancer disease life cycle Patient selection for therapy WILEX addresses markets

Documents
Dosage form factors influencing bioavailability Lec:5suli-pharma.com/uploads/lectures/5_Biopharmaceutics.pdf5.Composition and properties of capsule shell (including enteric capsules)

Dosage form factors influencing bioavailability Lec:5suli-pharma.com/uploads/lectures/5_Biopharmaceutics.pdf5.Composition and properties of capsule shell (including enteric capsules)

Documents
Investor Presentation · …with a proven track record of success… Market Share 7.0% Established in 2001 under the name “Ibnsina Laborex” in partnership with Pinault Printemps

Investor Presentation · …with a proven track record of success… Market Share 7.0% Established in 2001 under the name “Ibnsina Laborex” in partnership with Pinault Printemps

Documents
ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

Documents
Financial Statements-Consolidated - beximco-pharma.combeximco-pharma.com/investor/audited-annual... · Beximco Pharmaceuticals Limited and its Subsidiaries Report on the Audit of

Financial Statements-Consolidated - beximco-pharma.combeximco-pharma.com/investor/audited-annual... · Beximco Pharmaceuticals Limited and its Subsidiaries Report on the Audit of

Documents
Peptic ulcer disease - suli-pharma.com ulcer disease 2017.pdf · ! 1! Peptic’ulcer’disease ’! DrKawaAhmad! PhDPharmaceutics!! 1! GIT ! Foodtakenintothemouthismixedwithsalivatoformaplasticmass.Thesalivaryglands

Peptic ulcer disease - suli-pharma.com ulcer disease 2017.pdf · ! 1! Peptic’ulcer’disease ’! DrKawaAhmad! PhDPharmaceutics!! 1! GIT ! Foodtakenintothemouthismixedwithsalivatoformaplasticmass.Thesalivaryglands

Documents
Physicochemical Properties of Drugs Affecting Bioavailabilitysuli-pharma.com/uploads/lectures/4_Biopharmaceutics.pdf · 2019-11-29 · •Drug Factors affecting dissolution rate •Factors

Physicochemical Properties of Drugs Affecting Bioavailabilitysuli-pharma.com/uploads/lectures/4_Biopharmaceutics.pdf · 2019-11-29 · •Drug Factors affecting dissolution rate •Factors

Documents
PLATFORM - medtech-pharma.com€¦ · EU IVDR - Effect on companion diagnostic development Claudia Dollins, Merck ... Chair: Thomas Kühler, Sanofi Internet-of-Things (IoT) & connectivity

PLATFORM - medtech-pharma.com€¦ · EU IVDR - Effect on companion diagnostic development Claudia Dollins, Merck ... Chair: Thomas Kühler, Sanofi Internet-of-Things (IoT) & connectivity

Documents
Interim Financial Statements (Un-audited) - Beximco ...beximco-pharma.com/investor/half-yearly-report-2019-2020.pdfBeximco Pharmaceuticals Limited and its Subsidiaries Consolidated

Interim Financial Statements (Un-audited) - Beximco ...beximco-pharma.com/investor/half-yearly-report-2019-2020.pdfBeximco Pharmaceuticals Limited and its Subsidiaries Consolidated

Documents
DRAFT RED HERRING PROSPECTUS March 24 ... - calyx-pharma…calyx-pharma.com/new/Calyx_DRHP.pdf · CALYX CHEMICALS AND PHARMACEUTICALS LIMITED ... Golavli, Kalyan Shil Road, Dombivli

DRAFT RED HERRING PROSPECTUS March 24 ... - calyx-pharma…calyx-pharma.com/new/Calyx_DRHP.pdf · CALYX CHEMICALS AND PHARMACEUTICALS LIMITED ... Golavli, Kalyan Shil Road, Dombivli

Documents
5 solutions pour défendre l ... - smart-pharma.com€¦ · Confidentiel Smart Pharma Consulting Introduction Les politiques successives visant à maîtriser l’évolution des dépenses

5 solutions pour défendre l ... - smart-pharma.com€¦ · Confidentiel Smart Pharma Consulting Introduction Les politiques successives visant à maîtriser l’évolution des dépenses

Documents
LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

Documents
Company Update - Heidelberg Pharma GmbHheidelberg-pharma.com/wp-content/uploads/2015/01/... · 2019-06-26 · This communication contains certain forward-looking statements, relating

Company Update - Heidelberg Pharma GmbHheidelberg-pharma.com/wp-content/uploads/2015/01/... · 2019-06-26 · This communication contains certain forward-looking statements, relating

Documents
R&D Meeting - ds-pharma.com

R&D Meeting - ds-pharma.com

Documents